OpenAlex
PricingAboutJobs
Log inGet started
Author

K. Yamaguchi

Institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research
Observed institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research
ORCID: 0000-0001-6887-5709
Observed ORCID: 0000-0001-6887-5709
OpenAlex ID: A5121038917
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
2026 · Y.Y. Janjigian, K. Shitara, et al. · Annals of Oncology · 39
PDF
199MO First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study
2025 · T. Yoshino, T.W. Kim, et al. · Annals of Oncology
313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions
2025 · L. Shen, K. Shitara, et al. · Annals of Oncology
Works count: 3
Citation count: 39
H-index: 1
I10-index: 1
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms